6VP6

Cryo-EM structure of the C-terminal half of the Parkinson's Disease-linked protein Leucine Rich Repeat Kinase 2 (LRRK2)

6VP6 の概要

• エントリーDOI: 10.2210/pdb6vp6/pdb
• EMDBエントリー: 21250
• 分子名称: Leucine-rich repeat serine/threonine-protein kinase 2, GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION (3 entities in total)
• 機能のキーワード: kinase, gtpase, signaling protein
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 411298.33

構造登録者

Leschziner, A.,Deniston, C.,Lahiri, I. (登録日: 2020-02-01, 公開日: 2020-08-26, 最終更新日: 2024-11-06)

主引用文献

Deniston, C.K.,Salogiannis, J.,Mathea, S.,Snead, D.M.,Lahiri, I.,Matyszewski, M.,Donosa, O.,Watanabe, R.,Bohning, J.,Shiau, A.K.,Knapp, S.,Villa, E.,Reck-Peterson, S.L.,Leschziner, A.E.
Structure of LRRK2 in Parkinson's disease and model for microtubule interaction.
Nature, 588:344-349, 2020

PubMed Abstract: Leucine-rich repeat kinase 2 (LRRK2) is the most commonly mutated gene in familial Parkinson's disease and is also linked to its idiopathic form. LRRK2 has been proposed to function in membrane trafficking and colocalizes with microtubules. Despite the fundamental importance of LRRK2 for understanding and treating Parkinson's disease, structural information on the enzyme is limited. Here we report the structure of the catalytic half of LRRK2, and an atomic model of microtubule-associated LRRK2 built using a reported cryo-electron tomography in situ structure. We propose that the conformation of the LRRK2 kinase domain regulates its interactions with microtubules, with a closed conformation favouring oligomerization on microtubules. We show that the catalytic half of LRRK2 is sufficient for filament formation and blocks the motility of the microtubule-based motors kinesin 1 and cytoplasmic dynein 1 in vitro. Kinase inhibitors that stabilize an open conformation relieve this interference and reduce the formation of LRRK2 filaments in cells, whereas inhibitors that stabilize a closed conformation do not. Our findings suggest that LRRK2 can act as a roadblock for microtubule-based motors and have implications for the design of therapeutic LRRK2 kinase inhibitors.

PubMed: 32814344
DOI: 10.1038/s41586-020-2673-2

実験手法

ELECTRON MICROSCOPY (3.47 Å)